Published in J Breast Cancer on June 26, 2015
Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst (1990) 3.09
Dermatomyositis and malignancy. A review of the literature. Ann Intern Med (1976) 2.41
Clinical practice. Exanthematous drug eruptions. N Engl J Med (2012) 1.62
Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. Ann Rheum Dis (2001) 1.55
Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer. Anticancer Res (2012) 1.53
Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA (1986) 1.45
The relationship of dermatomyositis and polymyositis to internal malignancy. Arch Dermatol (1980) 1.33
Role of T cells in nonimmediate allergic drug reactions. Curr Opin Allergy Clin Immunol (2009) 1.05
Dermatomyositis associated with breast cancer. Anticancer Res (2006) 1.04
Immune mechanisms in polymyositis and dermatomyositis and potential targets for therapy. Rheumatology (Oxford) (2013) 0.92
NKp46+ cells express granulysin in multiple cutaneous adverse drug reactions. Allergy (2011) 0.90
Immune mechanisms in drug allergy. Allergol Int (2006) 0.88
Lymph Node Ratio as a Risk Factor for Locoregional Recurrence in Breast Cancer Patients with 10 or More Axillary Nodes. J Breast Cancer (2016) 0.85
Meeting highlights: the first korean breast cancer treatment consensus conference. J Breast Cancer (2014) 0.82
Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer. Oncotarget (2015) 0.79
Intra-tumoral Metastatic Double Primary Carcinoma: Synchronous Metastatic Tumor in Lung from Breast and Thyroid Carcinoma. Cancer Res Treat (2014) 0.75
Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results. Cancer Res Treat (2016) 0.75
Assessment of pathologic response and long-term outcome in locally advanced breast cancers after neoadjuvant chemotherapy: comparison of pathologic classification systems. Breast Cancer Res Treat (2016) 0.75
Characterization of Durable Responder for Capecitabine Monotherapy in Patients With Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer. Clin Breast Cancer (2015) 0.75